Omicron overpowers monoclonal antibody treatments in early tests

Preliminary experiments suggest that most of the monoclonal antibody treatments for Covid-19 are powerless against Omicron.

A slew of publications posted on preprint servers report laboratory evidence that Omicron is totally or partially resistant to all currently available treatments based on these monoclonal antibodies. The publications have not yet been peer reviewed, but some of the companies that manufacture antibody therapies already concede that their products have lower potency against Omicron than against other variants

Nature article: Omicron overpowers key COVID antibody treatments in early tests

 

 

 

 

Image by Mufid Majnun from Pixabay